145 related articles for article (PubMed ID: 37975967)
1. Use of patient-reported outcomes (PRO) data to complement exposure-response analysis in early clinical cancer drug development.
Xia H; Booth BP; Wang Y; Fan C; Bhatnagar V; Kluetz P; Fourie Zirkelbach J
J Patient Rep Outcomes; 2023 Nov; 7(1):116. PubMed ID: 37975967
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Kluetz PG; Chingos DT; Basch EM; Mitchell SA
Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
[TBL] [Abstract][Full Text] [Related]
3. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
[TBL] [Abstract][Full Text] [Related]
4. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bæksted C; Nissen A; Pappot H; Bidstrup PE; Mitchell SA; Basch E; Dalton SO; Johansen C
J Pain Symptom Manage; 2016 Aug; 52(2):292-7. PubMed ID: 27090851
[TBL] [Abstract][Full Text] [Related]
5. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
[TBL] [Abstract][Full Text] [Related]
6. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Basch E; Reeve BB; Mitchell SA; Clauser SB; Minasian LM; Dueck AC; Mendoza TR; Hay J; Atkinson TM; Abernethy AP; Bruner DW; Cleeland CS; Sloan JA; Chilukuri R; Baumgartner P; Denicoff A; St Germain D; O'Mara AM; Chen A; Kelaghan J; Bennett AV; Sit L; Rogak L; Barz A; Paul DB; Schrag D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25265940
[TBL] [Abstract][Full Text] [Related]
7. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
[TBL] [Abstract][Full Text] [Related]
8. Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag.
Davis S; Edwards T; Norcross L; Fehnel S; Beaudet A; Eckart M; Fastenau J
J Patient Rep Outcomes; 2023 Dec; 7(1):134. PubMed ID: 38108945
[TBL] [Abstract][Full Text] [Related]
9. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
[TBL] [Abstract][Full Text] [Related]
10. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
[TBL] [Abstract][Full Text] [Related]
12. Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®).
Caminiti C; Bryce J; Riva S; Ng D; Diodati F; Iezzi E; Sparavigna L; Novello S; Porta C; Del Mastro L; Procopio G; Cinieri S; Falzetta A; Calabrò F; Lorusso V; Cogoni AA; Tortora G; Maruzzo M; Passalacqua R; Cognetti F; Adamo V; Capelletto E; Ferrari A; Bagnalasta M; Bassi M; Nicelli A; De Persis D; D'Acunti A; Iannelli Patient E; Perrone F; Mitchell SA
Tumori; 2023 Jun; 109(3):324-334. PubMed ID: 35674125
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
Basch E; Pugh SL; Dueck AC; Mitchell SA; Berk L; Fogh S; Rogak LJ; Gatewood M; Reeve BB; Mendoza TR; O'Mara AM; Denicoff AM; Minasian LM; Bennett AV; Setser A; Schrag D; Roof K; Moore JK; Gergel T; Stephans K; Rimner A; DeNittis A; Bruner DW
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):409-418. PubMed ID: 28463161
[TBL] [Abstract][Full Text] [Related]
14. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bennett AV; Dueck AC; Mitchell SA; Mendoza TR; Reeve BB; Atkinson TM; Castro KM; Denicoff A; Rogak LJ; Harness JK; Bearden JD; Bryant D; Siegel RD; Schrag D; Basch E;
Health Qual Life Outcomes; 2016 Feb; 14():24. PubMed ID: 26892667
[TBL] [Abstract][Full Text] [Related]
15. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Basch E; Becker C; Rogak LJ; Schrag D; Reeve BB; Spears P; Smith ML; Gounder MM; Mahoney MR; Schwartz GK; Bennett AV; Mendoza TR; Cleeland CS; Sloan JA; Bruner DW; Schwab G; Atkinson TM; Thanarajasingam G; Bertagnolli MM; Dueck AC
Clin Trials; 2021 Feb; 18(1):104-114. PubMed ID: 33258687
[TBL] [Abstract][Full Text] [Related]
16. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Hay JL; Atkinson TM; Reeve BB; Mitchell SA; Mendoza TR; Willis G; Minasian LM; Clauser SB; Denicoff A; O'Mara A; Chen A; Bennett AV; Paul DB; Gagne J; Rogak L; Sit L; Viswanath V; Schrag D; Basch E;
Qual Life Res; 2014 Feb; 23(1):257-69. PubMed ID: 23868457
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
[TBL] [Abstract][Full Text] [Related]
18. Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.
Shepshelovich D; McDonald K; Spreafico A; Razak ARA; Bedard PL; Siu LL; Minasian L; Hansen AR
Oncologist; 2019 Apr; 24(4):e146-e148. PubMed ID: 30728278
[TBL] [Abstract][Full Text] [Related]
19. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.
Atkinson TM; Ryan SJ; Bennett AV; Stover AM; Saracino RM; Rogak LJ; Jewell ST; Matsoukas K; Li Y; Basch E
Support Care Cancer; 2016 Aug; 24(8):3669-76. PubMed ID: 27260018
[TBL] [Abstract][Full Text] [Related]
20. Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
Zhu Y; Jean-Baptiste M; Lenderking WR; Bell JA; Revicki DA; Lin HM; Brake R; Reeve BB
Cancer Med; 2023 Mar; 12(5):5494-5505. PubMed ID: 36583557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
